RxSight, Inc. sued for securities fraud by Bleichmar Fonti & Auld LLP.

A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. Investors have until September 22, 2025, to ask the Court to be appointed to lead the case.

Investors in RxSight, Inc. (NASDAQ: RXST) have been notified of a class action lawsuit alleging potential violations of federal securities laws. The lawsuit, filed by Glancy Prongay & Murray LLP RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit^[1], Bleichmar Fonti & Auld LLP RXSIGHT INVESTORS: New RxSight, Inc. Securities Class Action Filed relating to LDD Sales -- Contact BFA Law by September 22 Court Deadline^[2], and Levi & Korsinsky, LLP RxSight, Inc. Class Action: Levi & Korsinsky Reminds RxSight, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - RXST^[3], claims that the company and its senior executives made false statements and concealed material information from investors.

The lawsuit, pending in the U.S. District Court for the Central District of California, alleges that between November 7, 2024, and July 8, 2025, RxSight failed to disclose significant challenges and overstated the demand for its products. As a result, the company's positive statements about its business, operations, and prospects were materially misleading RXSIGHT INVESTORS: New RxSight, Inc. Securities Class Action Filed relating to LDD Sales -- Contact BFA Law by September 22 Court Deadline^[2].

Investors who purchased RxSight securities during this period are encouraged to participate in the lawsuit. They have until September 22, 2025, to ask the Court to appoint them as lead plaintiffs. The lead plaintiff will represent the interests of the class and share in any recovery [^1, 2, 3].

The lawsuit follows a series of financial forecasts cuts by RxSight, which cited "adoption challenges" and a slowdown in Light Adjustable Lens (LAL) utilization. On April 3, 2025, the company's stock price declined by approximately 38% after it cut its 2025 full-year revenue forecast. A further cut on July 8, 2025, led to a similar decline in stock price RXSIGHT INVESTORS: New RxSight, Inc. Securities Class Action Filed relating to LDD Sales -- Contact BFA Law by September 22 Court Deadline^[2].

Investors are advised to contact the respective law firms for more information and to submit their information to participate in the lawsuit. There is no cost to investors to participate, and any potential fees will be subject to court approval [^1, 2, 3].